SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chip

Chip is experiencing high volatility following its simultaneous listing on major trading platforms, sparking a fierce debate within the community regarding its long-term potential as an AI infrastructure token versus its risk as a potential pump-and-dump scheme. Investors are actively discussing the token's circulating supply, its connection to GPU-backed lending, and the aggressive short-selling activity that has emerged alongside its recent price swings.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic remains a subject of intense community debate, with proponents pointing to consistent monthly token burns by Binance and ecosystem developments like the LUNCVERSE as catalysts for a potential long-term recovery. Meanwhile, skeptics continue to label the asset a failed project, highlighting ongoing volatility and lingering sentiment from the original ecosystem collapse as key reasons for caution.

Airgain, Inc. provides embedded antenna products, integration support and test services. The firm works in partnership with the entire ecosystem, including carriers, chipset suppliers, OEMs, and ODMs. Its products include embedded, external and carrier-class antennas. The company offers custom antenna design and performance validation services. Its antennas are deployed in carrier, fleet, enterprise, residential, private, government, and public safety wireless networks and systems, including set-top boxes, access points, routers, modems, gateways, media adapters, and asset tracking devices. The company was founded on March 20,1995 and is headquartered in San Diego, CA.

Airgain Inc

Airgain Inc is trending following news of a multi-million dollar design win with a major U.S. utility to deploy its wireless connectivity technology across its fleet. Investors are actively discussing the potential impact of this contract and whether the company can maintain this momentum to drive long-term revenue growth.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is trending as traders discuss a potential short squeeze and high-volume price surge, with many speculating on the impact of upcoming governance proposals and Solana ecosystem growth. Community sentiment remains divided between those aggressively accumulating the asset for its perceived low-float upside and skeptics who are monitoring for signs of profit-taking or volatility.

FLOKI is a community-driven, multi-chain utility token that powers a broad ecosystem including decentralized gaming, finance, and educational platforms. Originally evolving from a meme-based asset, the project now focuses on a utility-driven model centered around three pillars: community engagement, technical utility, and global charity work, balancing this ecosystem growth with social impact, such as building schools in developing nations like Ghana and Nigeria.  Key features include Valhalla, an NFT metaverse game where the token serves as the primary currency for capturing creatures and upgrading characters. The ecosystem also features the FlokiFi Locker for securing digital assets and the University of FLOKI for web3 education,with real-world integration facilitated through a prepaid debit card for everyday purchases at global stores. Staking FLOKI allows users to earn rewards in a sister token.  The project is led by a group of core advisors known by pseudonyms such as Sabre and B (The Viking) and is officially backed by DWF Labs, a major digital asset investment firm and market maker. While a small tax on decentralized trades helps fund development, value moves through the system as users utilize the token to pay for in-game items, access asset-locking services, or purchase merchandise.

Floki Token

Floki is currently generating significant community buzz as investors focus on its expansion into institutional finance through ETP listings and ongoing ecosystem developments like the Valhalla metaverse. Supporters are actively discussing the token's potential for a broader meme sector rally, often highlighting its historical trend patterns and anticipation of future liquidity cycles.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is gaining significant traction as a high-conviction Solana project, with the community actively highlighting its robust supply control via a substantial on-chain locking program and a growing treasury. Investors are drawing parallels to the project's historical lore while focusing on its long-term stability and community-led development over short-term meme hype.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. Its products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits and embedded graphics. The company was founded in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

Silicon Motion is seeing significant volatility and investor interest following news that Chinese regulators have conditionally cleared its long-standing merger deal with MaxLinear. The community is actively debating the implications of the acquisition's path forward, with traders closely monitoring the spread between the current price and the deal's implied value as they navigate heightened volume and regulatory uncertainty.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The PEPE community is buzzing with bullish sentiment as investors leverage recent market volatility to accumulate tokens, while actively debating the potential impact of ETF filings on the coin's future. Discussions are heavily focused on the coin's long-term potential as a 'blue-chip' meme, with many members sharing price predictions and coordinating accumulation strategies during current consolidation phases.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently sparking intense debate within the community, with many investors actively accumulating during the current price consolidation while others express frustration over the lack of major project milestones and price momentum. Sentiment remains deeply polarized between those maintaining long-term conviction in the project's utility and those concerned by the significant lag in performance compared to broader market trends.

GLOBALFOUNDRIES, Inc. provides foundry services and manufactures semiconductors. It offers global shuttle, mask, post-fab and turnkey services. The company was founded on October 7, 2008 and is headquartered in Malta, NY.

GlobalFoundries Inc

GlobalFoundries is currently drawing investor attention due to its strategic role as a domestic foundry player, benefiting from U.S. CHIPS Act funding and increasing interest in onshored semiconductor manufacturing for AI, defense, and power systems. Community sentiment highlights it as a critical 'picks and shovels' enabler that remains under-owned compared to high-profile AI stocks, with ongoing discussions focusing on the potential for long-term supply chain resilience and its positioning within the evolving semiconductor ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$INBX Why still has 5–10x move in front of it.

Management has been saying ~$500M peak each for Ewing + chondrosarcoma - $1B combined.

This level makes sense with literally no approved systemic therapy in either indication.

Look at what similar rare oncology drugs have actually done. Larotrectinib/entrectinib in NTRK fusions and pemigatinib in FGFR2+ cholangiocarcinoma are hitting $400–800M+ peak sales at premium orphan pricing with strong data and good penetration.

For $INBX to hit that $1B combined number they basically need solid pricing, high share in the metastatic/recurrent setting, and some label expansion, especially perioperative for chondrosarcoma. The recent liver mets safety data from the CRC update helps here too.

With just chondro + Ewing you’re probably looking at $4–5B of value at 4-5x peak sales ($190–240/share, assuming slight dilution). Add 4L accelerated approval and it moves into the $5.5–6.5B range pretty easily ($260–310/share).

Yoda

Daniel

mike wilson

Shabbir khambati

StockTwits for iOS

Inhibrx Inc

 Why still has 5–10x move in front of it.

Management has been saying ~$500M peak each for Ewing + chondrosarcoma - $1B combined.

This level makes sense with literally no approved systemic therapy in either indication.

Look at what similar rare oncology drugs have actually done. Larotrectinib/entrectinib in NTRK fusions and pemigatinib in FGFR2+ cholangiocarcinoma are hitting $400–800M+ peak sales at premium orphan pricing with strong data and good penetration.

For 

 to hit that $1B combined number they basically need solid pricing, high share in the metastatic/recurrent setting, and some label expansion, especially perioperative for chondrosarcoma. The recent liver mets safety data from the CRC update helps here too.

With just chondro + Ewing you’re probably looking at $4–5B of value at 4-5x peak sales ($190–240/share, assuming slight dilution). Add 4L accelerated approval and it moves into the $5.5–6.5B range pretty easily ($260–310/share).

Quince Therapeutics Inc

SPDR S&P Biotech ETF

Innventure inc.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

CalciMedica Inc

Enovix Corp

BullStockpicks1

And if pharma starts seeing a clear line of sight to 1-3L CRC expansion on top of that, you’re talking $8B + potential ($380–475+/share).

Stifel just raised their PT to $300 and bumped 109 peak sales to over $10B on the CRC signals — which lines up with the upper end of what we’re modeling here.

This is why the stock is still way undervalued here, it gives basically zero credit for 106. Management has said the total addressable market for 106 is $50B + across PD-1 indications. Even if it only captures a meaningful slice with strong head-to-head data vs Keytruda, this could easily be worth $400–$1,200+ per share on its own in a bull case. This is why 106 is not even remotely priced in yet and we are a few weeks away from key data readout. It would make no sense for management to have taken an unblinded study this far without positive results.

Combined, you’re looking at $800–1,200+ per share, with significantly more upside if 106 is truly exceptional.  The downside here is upside to 109, which makes for a crazy and rare opportunity 

I haven’t sold a share and the best biotechs are the ones that are showing validation but still mis-priced; and that is what I see here with 5-10x+ potential remaining.

Not advice. DYOR. Long $INBX $XBI

Combined, you’re looking at $800–1,200+ per share, with significantly more upside if 106 is truly exceptional.  The downside here is upside to 109, which makes for a crazy and rare opportunity 

I haven’t sold a share and the best biotechs are the ones that are showing validation but still mis-priced; and that is what I see here with 5-10x+ potential remaining.

Not advice. DYOR. Long 

@BullStockpicks1 There will be some dilution (need to raise money) if they commercialize 109 for chondro and take it to earlier lines testing in colorectal on their own, but this is easily $600-$1000/share,at the latest when PFS data on 106 comes out if successful (later this year?).

StockTwits Web

 There will be some dilution (need to raise money) if they commercialize 109 for chondro and take it to earlier lines testing in colorectal on their own, but this is easily $600-$1000/share,at the latest when PFS data on 106 comes out if successful (later this year?).

Number99

@BullStockpicks1 how come you think it’ll be first or second week of May specifically for 106 readout ? also, assuming buyers are circling them, then i’m sure they’d get to see 106 before us? and if it’s good enough, we might just wake up to a buyout rather than even seeing the data?

 how come you think it’ll be first or second week of May specifically for 106 readout ? also, assuming buyers are circling them, then i’m sure they’d get to see 106 before us? and if it’s good enough, we might just wake up to a buyout rather than even seeing the data?

Booking Holdings Inc

SPDR Gold Shares ETF

Lilly(Eli) & Co

Novo Nordisk A/S

Altimmune Inc

Liquidia Corp

Structure Therapeutics Inc - ADR

@judgeyoung2 that is what I am hearing.  I don’t see sale until some of the data develops but you never know!

 that is what I am hearing.  I don’t see sale until some of the data develops but you never know!

@BullStockpicks1 but you do see a potential for double on the interim data itself ?

 but you do see a potential for double on the interim data itself ?

@judgeyoung2 you never know how the market will react but I see no evidence that 106 is remotely in the current price and it is a bigger TAM than 109.

 you never know how the market will react but I see no evidence that 106 is remotely in the current price and it is a bigger TAM than 109.

@BullStockpicks1 like you’ve said, the discount cannot be ignored. they’re not even pricing in 106 at all. so, risk / reward is worth it.

 like you’ve said, the discount cannot be ignored. they’re not even pricing in 106 at all. so, risk / reward is worth it.

@judgeyoung2 yes I can’t see how 109 with where we sit would go for anything less than $250 a share

 yes I can’t see how 109 with where we sit would go for anything less than $250 a share